Dr. Wenning Qin is SVP, Innovation at eGenesis, and is responsible for editing of the porcine genome for the purpose of developing human compatible cells, tissues, and organs to advance products for transplantation.
Dr. Qin has over 25 years of experience in gene editing and scientific leadership spanning Monsanto Life Sciences, Pharmacia Corporation, Pfizer Inc., Biogen Idec, and the Jackson Laboratory. Numerous programs Dr. Qin supported – across oncology, neuroscience, cardiovascular disease – have advanced to IND and approval.
Across her career, Dr. Qin has specialized in genome editing in model organisms, including rodent and porcine models, employing conventional gene targeting as well as the CRISPR-Cas9 genome editing technology.
Dr. Qin earned a B.S. in Public Health and a M.S. in Cardiovascular Physiology from Tongji Medical University, and a Ph.D. in cardiovascular pharmacology from Southern Illinois University. Dr. Qin completed postdoctoral training in transcriptional regulation of gene expression at Washington University School of Medicine.